journal article·2023-09-18Open access

Radiolabeled Human Serum Albumin Nanoparticles Co-Loaded with Methotrexate and Decorated with Trastuzumab for Breast Cancer Diagnosis

Meliha Ekinci, Luciana Magalhães Rebelo Alencar, André Moreni Lopes, Ralph Santos-Oliveira, Derya İlem-Özdemir

Abstract

Breast cancer is a leading cause of cancer-related mortality among women worldwide, with millions of new cases diagnosed yearly. Addressing the burden of breast cancer mortality requires a comprehensive approach involving early detection, accurate diagnosis, effective treatment, and equitable access to healthcare services. In this direction, nano-radiopharmaceuticals have shown potential for enhancing breast cancer diagnosis by combining the benefits of nanoparticles and radiopharmaceutical agents. These nanoscale formulations can provide improved imaging capabilities, increased targeting specificity, and enhanced sensitivity for detecting breast cancer lesions. In this study, we developed and evaluated a novel nano-radio radiopharmaceutical, technetium-99m ([99mTc]Tc)-labeled trastuzumab (TRZ)-decorated methotrexate (MTX)-loaded human serum albumin (HSA) nanoparticles ([99mTc]-TRZ-MTX-HSA), for the diagnosis of breast cancer. In this context, HSA and MTX-HSA nanoparticles were prepared. Conjugation of MTX-HSA nanoparticles with TRZ was performed using adsorption and covalent bonding methods. The prepared formulations were evaluated for particle size, PDI value, zeta (ζ) potential, scanning electron microscopy analysis, encapsulation efficiency, and loading capacity and cytotoxicity on MCF-7, 4T1, and MCF-10A cells. Finally, the nanoparticles were radiolabeled with [99mTc]Tc using the direct radiolabeling method, and cellular uptake was performed with the nano-radiopharmaceutical. The results showed the formation of spherical nanoparticles, with a particle size of 224.1 ± 2.46 nm, a PDI value of 0.09 ± 0.07, and a ζ potential value of −16.4 ± 0.53 mV. The encapsulation efficiency of MTX was found to be 32.46 ± 1.12%, and the amount of TRZ was 80.26 ± 1.96%. The labeling with [99mTc]Tc showed a high labeling efficiency (>99%). The cytotoxicity studies showed no effect, and the cellular uptake studies showed 97.54 ± 2.16% uptake in MCF-7 cells at the 120th min and were found to have a 3-fold higher uptake in cancer cells than in healthy cells. In conclusion, [99mTc]Tc-TRZ-MTX-HSA nanoparticles are promising for diagnosing breast cancer and evaluating the response to treatment in breast cancer patients.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Radiopharmaceutical Chemistry and Applications · Nanoparticle-Based Drug Delivery · Radiation Therapy and Dosimetry

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Faculty of Pharmacy, Department of Radiopharmacy, Ege University, Bornova, Izmir 35040, Turkey

Biophysics and Nanosystems Laboratory, Department of Physics, Federal University of Maranhão, São Luis 65065-690, Brazil

Department of Biotechnology, Engineering School of Lorena, University of São Paulo (EEL/USP), São Paulo 12612-550, Brazil

Laboratory of Nanoradiopharmacy and Synthesis of Novel Radiopharmaceuticals, Nuclear Engineering Institute, Brazilian Nuclear Energy Commission, Rio de Janeiro 21941-906, Brazil

Laboratory of Radiopharmacy and Nanoradiopharmaceuticals, State University of Rio de Janeiro, Rio de Janeiro 23070-200, Brazil

Funding

Ege University Scientific Research Projects Coordination Unit

References (78)

Show source-provided references
1. Breast Cancer, and World Health Organization (2023, January 01). 2023 [Kaynak 08 Haziran 2023]. Available online: https://www.who.int/news-room/fact-sheets/detail/breast-cancer.
2. Formulation and development of transferrin targeted solid lipid nanoparticles for breast cancer therapy10.3389/fphar.2020.614290 ↗
3. Aldawsari, H.M., and Singh, S. (2020). Rapid microwave-assisted cisplatin-loaded solid lipid nanoparticles: Synthesis, characterization and anticancer study. Nanomaterials, 10.10.3390/nano10030510 ↗
4. Breast cancer early detection: A phased approach to implementation10.1002/cncr.32887 ↗
5. Ultrasmall targeted nanoparticles with engineered antibody fragments for imaging detection of HER2-overexpressing breast cancer10.1038/s41467-018-06271-5 ↗
6. Near-infrared fluorescence imaging for noninvasive trafficking of scaffold degradation10.1038/srep01198 ↗
7. Nanoparticle-enhanced radiotherapy to trigger robust cancer immunotherapy10.1002/adma.201802228 ↗
8. Aptamer-conjugated nanomaterials for specific cancer cell recognition and targeted cancer therapy10.1038/am.2014.12 ↗
9. Sitia, L., Sevieri, M., Signati, L., Bonizzi, A., Chesi, A., and Mainini, F. (2022). HER-2-targeted nanoparticles for breast cancer diagnosis and treatment. Cancers, 14.10.3390/cancers14102424 ↗
10. Radioactive gold nanocluster (198-AuNCs) showed inhibitory effects on cancer cells lines10.1080/21691401.2020.1821698 ↗
11. Nanoradiopharmaceuticals for breast cancer imaging: Development, characterization, and imaging in inducted animals10.2147/OTT.S110787 ↗
12. 99mTc- Anionic dendrimer targeted vascular endothelial growth factor as a novel nano-radiotracer for in-vivo breast cancer imaging10.1016/j.bioorg.2022.106085 ↗
13. Amelioration of tumor targeting and in vivo biodistribution of 99mTc-methotrexate-gold nanoparticles (99mTc-Mex-AuNPs)10.1016/j.xphs.2021.03.021 ↗
14. 99mTc Tamoxifen for imaging estrogen receptor expression in metastatic breast cancer patient10.1097/RLU.0000000000002900 ↗
15. Molecular breast imaging: A comprehensive review10.1053/j.sult.2017.10.001 ↗
16. Yamaguchi, H., Tsuchimochi, M., Hayama, K., Kawase, T., and Tsubokawa, N. (2016). Dual-labeled near-infrared/99mTc imaging probes using PAMAM-coated silica nanoparticles for the imaging of HER2-expressing cancer cells. Int. J. Mol. Sci., 17.10.3390/ijms17071086 ↗
17. 99mTc-radiolabeled silica nanocarriers for targeted detection and treatment of HER2-positive breast cancer10.2147/IJN.S276033 ↗
18. Molecular imaging of HER2 expression in breast cancer patients using the [99mTc] Tc-labeled small peptide10.1016/j.clbc.2022.12.002 ↗
19. Anti-MUC1 nano-aptamers for triple-negative breast cancer imaging by single-photon emission computed tomography in inducted animals: Initial considerations
20. Use of biotin targeted methotrexate-human serum albumin conjugated nanoparticles to enhance methotrexate antitumor efficacy
21. Differential tumor cell targeting of anti-HER2 (Herceptin®) and anti-CD20 (Mabthera®) coupled nanoparticles10.1016/j.ijpharm.2006.12.002 ↗
22. Trastuzumab decorated methotrexate-human serum albumin conjugated nanoparticles for targeted delivery to HER2 positive tumor cells10.1016/j.ejps.2012.06.016 ↗
23. The role of HER2 in cancer therapy and targeted drug delivery10.1016/j.jconrel.2010.04.009 ↗
24. Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles10.1021/bc8002452 ↗
25. Methotrexate loaded chitosan nanoparticles: Preparation, radiolabeling and in vitro evaluation for breast cancer diagnosis10.1016/j.jddst.2015.10.004 ↗
26. Koźmiński, P., Halik, P.K., Chesori, R., and Gniazdowska, E. (2020). Overview of dual-acting drug methotrexate in different neurological diseases, autoimmune pathologies and cancers. Int. J. Mol. Sci., 21.10.3390/ijms21103483 ↗
27. Enhanced anti-tumoral activity of methotrexate-human serum albumin conjugated nanoparticles by targeting with luteinizing hormone-releasing hormone (LHRH) peptide10.3390/ijms12074591 ↗
28. Human serum albumin nanoparticles as an efficient noscapine drug delivery system for potential use in breast cancer: Preparation and in vitro analysis
29. Shell cross-linked and hepatocyte-targeting nanoparticles containing doxorubicin via acid-cleavable linkage10.1016/j.nano.2010.07.001 ↗
30. Lomis, N., Westfall, S., Farahdel, L., Malhotra, M., Shum-Tim, D., and Prakash, S. (2016). Human serum albumin nanoparticles for use in cancer drug delivery: Process optimization and in vitro characterization. Nanomaterials, 6.10.3390/nano6060116 ↗
31. Human serum albumin nanoparticles as a versatile vehicle for targeted delivery of antibiotics to combat bacterial infections10.1016/j.nano.2023.102685 ↗
32. Global challenges in breast cancer detection and treatment10.1016/j.breast.2022.02.003 ↗
33. A review on methods for diagnosis of breast cancer cells and tissues10.1111/cpr.12822 ↗
34. Radiolabeled nanomaterial for cancer diagnostics and therapeutics: Principles and concepts10.1186/s12645-023-00165-y ↗
35. Development and preclinical evaluation of a near-infrared fluorescence probe based on tailored hepatitis B Core particles for imaging-guided surgery in breast cancer10.2147/IJN.S343479 ↗
36. Cancer nanotargeted radiopharmaceuticals for tumor imaging and therapy
37. Nanoparticles for imaging and treatment of metastatic breast cancer10.1080/17425247.2016.1208650 ↗
38. Optimization the Preparation Process of Methotrexate Loaded Human Serum Albumin Nanoparticles. Içinde: 12th International Symposium on Pharmaceutical Sciences
39. Optimization of the preparation process for human serum albumin (HSA) nanoparticles10.1016/S0378-5173(03)00134-0 ↗
40. Human serum albumin (HSA) nanoparticles stabilized with intermolecular disulfide bonds10.1039/c3cc38397k ↗
41. Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody10.1016/j.jconrel.2007.03.012 ↗
42. RP-HPLC method for estimation of ado-trastuzumabe emtansine injection in pharmaceutical dosage form
43. Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells10.1016/j.biopha.2014.01.002 ↗
44. Effect of hydrophobicity on intercalative binding of some surfactant copper(II) complexes with tRNA10.1007/s00706-014-1267-9 ↗
45. Characterization, optimization, and in vitro evaluation of Technetium-99m-labeled niosomes10.2147/IJN.S184912 ↗
46. Development and in vitro evaluation of positive-charged solid lipid nanoparticles as nucleic acid delivery system in glioblastoma treatment10.12991/mpj.2018.67 ↗
47. Principles of nanoparticle design for overcoming biological barriers to drug delivery10.1038/nbt.3330 ↗
48. Paclitaxel-loaded folate-coated long circulating and pH-sensitive liposomes as a potential drug delivery system: A biodistribution study10.1016/j.biopha.2017.10.135 ↗
49. Danaei, M., Dehghankhold, M., Ataei, S., Hasanzadeh Davarani, F., Javanmard, R., and Dokhani, A. (2018). Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics, 10.10.3390/pharmaceutics10020057 ↗
50. Effect of chemical composition and sonication procedure on properties of food-grade soy lecithin liposomes with added glycerol10.1016/j.foodres.2017.07.052 ↗
51. Skin penetration and deposition of carboxyfluorescein and temoporfin from different lipid vesicular systems: In vitro study with finite and infinite dosage application10.1016/j.ijpharm.2011.02.006 ↗
52. Formulation, characterization and optimization of liposomes containing eicosapentaenoic and docosahexaenoic acids; A methodology approach
53. Physico-chemical stability of colloidal lipid particles10.1016/S0142-9612(03)00331-4 ↗
54. Synthesis, pharmacoscintigraphic evaluation and antitumor efficacy of methotrexate-loaded, folate-conjugated, stealth albumin nanoparticles10.2217/nnm.11.53 ↗
55. Saeidi, M., Chenani, H., Orouji, M., Adel Rastkhiz, M., Bolghanabadi, S., Vakili, N., Mohamadnia, Z., Hatamie, A., and Simchi, A. (2023). Electrochemical Wearable Biosensors and Bioelectronic Devices Based on Hydrogels: Mechanical Properties and Electrochemical Behavior. Biosensors, 13.10.20944/preprints202306.0187.v1 ↗
56. Purely covalent molecular cages and containers for guest encapsulation10.1021/acs.chemrev.2c00198 ↗
57. Carbon nanotube chemical sensors10.1021/acs.chemrev.8b00340 ↗
58. Ahmad, F., Salem-Bekhit, M.M., Khan, F., Alshehri, S., Khan, A., Ghoneim, M.M., Wu, H.F., Taha, E.I., and Elbagory, I. (2022). Unique properties of surface-functionalized nanoparticles for bio-application: Functionalization mechanisms and importance in application. Nanomaterials, 12.10.3390/nano12081333 ↗
59. The smart targeting of nanoparticles10.2174/13816128113199990375 ↗
60. Krause, W. (2005). 6-Hydrazinonicotinamide Derivatives as Bifunctional Coupling Agents for 99mTc-Labeling of Small Biomolecules, Springer. Contrast Agents III Topics in Current Chemistry.10.1007/b94549 ↗
61. Preparation, characterization, and biodistribution study of technetium-99m-labeled leuprolide acetate-loaded liposomes in ehrlich ascites tumor-bearing mice10.1208/ps060105 ↗
62. Radiolabeling, pharmacoscintigraphic evaluation and antiretroviral efficacy of stavudine loaded 99mTc labeled galactosylated liposomes10.1016/j.ejps.2007.12.006 ↗
63. Review on 99mTc radiopharmaceuticals with emphasis on new advancements10.1016/j.nucmedbio.2020.05.005 ↗
64. Synthesis, 99mTc-labeling, and preliminary biological evaluation of DTPA-melphalan conjugates10.1002/jlcr.3575 ↗
65. Practical considerations for navigating the regulatory landscape of non-clinical studies for clinical translation of radiopharmaceuticals10.1186/s41181-022-00168-x ↗
66. Nanoparticulate formulations of radiopharmaceuticals: Strategy to improve targeting and biodistribution properties10.1002/jlcr.3839 ↗
67. Nanoparticles for cancer diagnosis, radionuclide therapy and theranostics10.1021/acsnano.1c09139 ↗
68. Immune activity and biodistribution of polypeptide K237 and folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles radiolabeled with 99mTc10.18632/oncotarget.12850 ↗
69. MCF-7 cells—Changing the course of breast cancer research and care for 45 years10.1093/jnci/djv073 ↗
70. The story of MCF-7 breast cancer cell line: 40 years of experience in research
71. Mouse 4T1 breast tumor model10.1002/0471142735.im2002s39 ↗
72. Intraductal adaptation of the 4T1 mouse model of breast cancer reveals effects of the epithelial microenvironment on tumor progression and metastasis10.21873/anticanres.13344 ↗
73. Mouse models of breast cancer metastasis10.1186/bcr1530 ↗
74. Qu, Y., Han, B., Yu, Y., Yao, W., Bose, S., Karlan, B.Y., Giuliano, A.E., and Cui, X. (2015). Evaluation of MCF10A as a reliable model for normal human mammary epithelial cells. PLoS ONE, 10.10.1371/journal.pone.0131285 ↗
75. A novel MCF-10A line allowing conditional oncogene expression in 3D culture10.1186/1478-811X-9-17 ↗
76. Is it time to start transitioning from 2D to 3D cell culture?10.3389/fmolb.2020.00033 ↗
77. Radiolabeling strategies for tumor-targeting proteinaceous drugs10.3390/molecules19022135 ↗
78. Biomarkers in molecular medicine: Cancer detection and diagnosis10.2144/05384SU04 ↗